Science may be one step closer to treating diabetes with a human probiotic pill, according to new Cornell University research.
In the study, published Jan. 27 in the journal Diabetes, the researchers engineered a strain of lactobacillus, a human probiotic common in the gut, to secrete a Glucagon-like peptide 1 (GLP-1). They then administered it orally to diabetic rats for 90 days and found the rats receiving the engineered probiotic had up to 30 percent lower high blood glucose, a hallmark of diabetes.
The study was a proof of principle, and future work will test higher doses to see if a complete treatment can be achieved, said John March, professor of biological and environmental engineering at Cornell University and the paper's senior author.
The researchers found that upper intestinal epithelial cells in diabetic rats were converted into cells that acted very much like pancreatic beta cells, which monitor blood glucose levels and secrete insulin as needed to balance glucose levels in healthy individuals.
"The amount of time to reduce glucose levels following a meal is the same as in a normal rat, ... and it is matched to the amount of glucose in the blood," just as it would be with a normal-functioning pancreas, March said. "It's moving the center of glucose control from the pancreas to the upper intestine."
Also, though it replaces the insulin capacity in diabetic rats, the researchers found no change in blood glucose levels when administered to healthy rats. "If the rat is managing its glucose, it doesn't need more insulin," March said.
This technology was licensed by the BioPancreate, a wholly-owned subsidiary of Cortendo AB, a biopharmaceutical company incorporated in Sweden and based in Radnor, Penn., which is working to get the therapy into production for human use.
Human patients would likely take a pill each morning to help control their diabetes, March said.
The study is funded by the National Institutes of Health and the Hartwell Foundation.
Cornell University has television, ISDN and dedicated Skype/Google+ Hangout studios available for media interviews.
Melissa Osgood | EurekAlert!
Molecular evolution: How the building blocks of life may form in space
26.04.2018 | American Institute of Physics
Multifunctional bacterial microswimmer able to deliver cargo and destroy itself
26.04.2018 | Max-Planck-Institut für Intelligente Systeme
Magnetic resonance imaging, or MRI, is a widely used medical tool for taking pictures of the insides of our body. One way to make MRI scans easier to read is...
At the Hannover Messe 2018, the Bundesanstalt für Materialforschung und-prüfung (BAM) will show how, in the future, astronauts could produce their own tools or spare parts in zero gravity using 3D printing. This will reduce, weight and transport costs for space missions. Visitors can experience the innovative additive manufacturing process live at the fair.
Powder-based additive manufacturing in zero gravity is the name of the project in which a component is produced by applying metallic powder layers and then...
Physicists at the Laboratory for Attosecond Physics, which is jointly run by Ludwig-Maximilians-Universität and the Max Planck Institute of Quantum Optics, have developed a high-power laser system that generates ultrashort pulses of light covering a large share of the mid-infrared spectrum. The researchers envisage a wide range of applications for the technology – in the early diagnosis of cancer, for instance.
Molecules are the building blocks of life. Like all other organisms, we are made of them. They control our biorhythm, and they can also reflect our state of...
University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.
Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.
Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.
Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...
13.04.2018 | Event News
12.04.2018 | Event News
09.04.2018 | Event News
26.04.2018 | Physics and Astronomy
26.04.2018 | Life Sciences
26.04.2018 | Medical Engineering